CTLA4 and melanoma: Since anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) was approved for advanced melanoma treatment in 2011, ICIs have rapidly gained approval and been used to treat various cancers, which has led to an unprecedented increase in survival [3–5].